D.A. Davidson & CO. grew its holdings in PRA Health Sciences Inc (NASDAQ:PRAH) by 51.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,898 shares of the medical research company’s stock after purchasing an additional 1,659 shares during the quarter. D.A. Davidson & CO.’s holdings in PRA Health Sciences were worth $446,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also made changes to their positions in the company. IFP Advisors Inc lifted its stake in shares of PRA Health Sciences by 19,083.3% in the 4th quarter. IFP Advisors Inc now owns 1,151 shares of the medical research company’s stock valued at $105,000 after purchasing an additional 1,145 shares during the period. Carroll Financial Associates Inc. lifted its stake in shares of PRA Health Sciences by 127.4% in the 3rd quarter. Carroll Financial Associates Inc. now owns 1,410 shares of the medical research company’s stock valued at $112,000 after purchasing an additional 790 shares during the period. Intrust Bank NA acquired a new position in shares of PRA Health Sciences in the 4th quarter valued at about $204,000. Parametrica Management Ltd acquired a new position in shares of PRA Health Sciences in the 4th quarter valued at about $232,000. Finally, Comerica Bank acquired a new position in shares of PRA Health Sciences in the 3rd quarter valued at about $214,000. 97.15% of the stock is currently owned by institutional investors.
PRA Health Sciences Inc (NASDAQ PRAH) opened at $86.18 on Friday. PRA Health Sciences Inc has a 52 week low of $57.72 and a 52 week high of $95.90. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.01 and a current ratio of 1.01. The firm has a market capitalization of $5,639.27, a P/E ratio of 65.29, a P/E/G ratio of 1.21 and a beta of 0.32.
PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings results on Wednesday, February 21st. The medical research company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.02. PRA Health Sciences had a return on equity of 23.33% and a net margin of 3.85%. The business had revenue of $568.80 million for the quarter, compared to the consensus estimate of $543.78 million. During the same period in the prior year, the business earned $0.71 EPS. The firm’s revenue for the quarter was up 37.5% on a year-over-year basis. analysts anticipate that PRA Health Sciences Inc will post 3.97 earnings per share for the current year.
A number of research analysts have recently issued reports on the company. Zacks Investment Research raised PRA Health Sciences from a “hold” rating to a “buy” rating and set a $103.00 price objective on the stock in a research note on Thursday, January 11th. BidaskClub downgraded PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, February 2nd. SunTrust Banks reissued a “buy” rating and issued a $101.00 price objective on shares of PRA Health Sciences in a research note on Friday, October 27th. Credit Suisse Group reissued an “outperform” rating and issued a $104.00 price objective (up from $101.00) on shares of PRA Health Sciences in a research note on Thursday. Finally, Barclays began coverage on PRA Health Sciences in a research note on Monday, December 11th. They set an “overweight” rating and a $94.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. PRA Health Sciences presently has an average rating of “Buy” and a consensus price target of $93.15.
In other PRA Health Sciences news, insider David W. Dockhorn sold 72,850 shares of the business’s stock in a transaction that occurred on Thursday, December 28th. The stock was sold at an average price of $90.83, for a total transaction of $6,616,965.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Linda Baddour sold 67,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $90.27, for a total value of $6,048,090.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 212,700 shares of company stock worth $19,282,021. 2.10% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/24/pra-health-sciences-inc-prah-stake-lifted-by-d-a-davidson-co.html.
PRA Health Sciences Profile
PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.